# Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours

> **NCT00697879** · PHASE1 · COMPLETED · sponsor: **Chroma Therapeutics** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CHR-3996

## Key facts

- **NCT ID:** NCT00697879
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-11
- **Final completion:** 2011-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2011-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697879, "Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00697879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*